Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This research aims to compare the effects of Hatha yoga and reformer Pilates exercises on individuals with hyperkyphosis, a condition where an increased curvature of the spine leads to poor posture, back pain, balance problems, and respiratory difficulties. Hyperkyphosis is linked to muscle weakness and poor posture habits, especially in adolescents and older adults, and can impact quality of life, body image, and physical function. Participants will be assigned to one of three groups a control group performing a home exercise program, a Hatha yoga group exercising three times a week for eight weeks with sessions lasting 45 minutes led by a certified instructor focusing on postural control and breathing, or a reformer Pilates group with the same exercise frequency and session length led by a certified Pilates instructor focusing on posture. All groups receive a home program and weekly telephone follow-up during the eight-week period. During the study, participants will undergo various assessments at the start and after eight weeks, including posture evaluation scales, measurements of kyphosis angle, pain scales, balance tests, quality of life questionnaires, body image assessments, pulmonary function tests, and body composition measurements. Researchers will monitor changes in posture, pain, balance, respiratory function, body image, and quality of life. The study includes physical exams and regular follow-up to evaluate the effects of these exercise programs on hyperkyphosis.
Actively Recruiting
Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer that has an ESR1 mutation. This study focuses on patients who have previously received ribociclib or palbociclib-based treatment and aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants will receive either 5 mg per day of oral lasofoxifene plus oral abemaciclib 150 mg twice daily, or fulvestrant 500 mg given intramuscularly on Days 1, 15, and 29, then once monthly thereafter, combined with oral abemaciclib 150 mg twice daily. The study is randomized and open-label, allowing comparison between these two treatment combinations over time. During the study, participants will be closely monitored for progression-free survival, objective response rate, overall survival, clinical benefit rate, duration and time to response, time to cytotoxic chemotherapy, quality of life using a specific breast cancer assessment tool, and the incidence of adverse events. The study includes various assessments and safety monitoring over approximately three years to evaluate these outcomes and the participants response to the treatments.
Actively Recruiting
Researchers are evaluating the pharmacokinetics similarity, safety, and immune response between Bmab1700, an intended biosimilar to nivolumab, and the United States-licensed Opdivo in participants who have had complete surgical removal of melanoma. The study focuses on adults with Stage IIB, IIC, III, or IV melanoma that has been fully resected. This phase 1 trial aims to compare these treatments as adjuvant monotherapy after surgery to understand their behavior in the body and their safety. Participants are randomly assigned to one of two groups. In the first 24 weeks Double-Blind Treatment Period, they receive intravenous infusions of either Bmab1700 or Opdivo every four weeks until disease relapse, unacceptable toxicity, or Week 20, whichever comes first. After Week 24, participants who continue in the study enter an Open-Label Treatment Period where all receive Bmab1700 every four weeks until Week 48, followed by an end-of-study visit at Week 52. Throughout the study, participants undergo regular assessments including blood sampling for drug concentration and immune response measures, monitoring for adverse events, and physical exams. Researchers measure drug levels over time, immune antibody development, and safety outcomes to evaluate the treatments. The total participation lasts up to 52 weeks, with careful monitoring to track treatment effects and participant health.
Actively Recruiting
This clinical trial studies seladelpar, a drug being evaluated for its effects on people with primary biliary cholangitis PBC who have compensated cirrhosis. The main goal is to compare seladelpar with a placebo to see how it impacts event-free survival EFS, which measures the time until certain liver-related events occur over a period of up to 156 weeks. This research is led by Gilead Sciences and takes place in a phase 3 setting, aiming to better understand treatment outcomes for PBC patients with cirrhosis. Participants with Child-Pugh class A cirrhosis will receive 10 mg of seladelpar orally once daily, while those with Child-Pugh class B will receive 5 mg once daily, both for up to 36 months. Another group with either Child-Pugh class A or B will receive a placebo matching the study drug daily for the same duration. After 156 weeks, participants with Child-Pugh class A or B who remain on the study drug may continue seladelpar at the respective doses for an additional maximum of 3 years during an open-label extension phase. Participants will be monitored throughout the study with regular assessments to evaluate liver function and clinical events related to PBC and cirrhosis. Researchers will measure outcomes such as event-free survival, overall survival, time to hospitalization, and liver transplant-free survival. Safety and liver health will be closely followed using laboratory tests and imaging. The total participation time may extend up to several years, depending on continued study drug use and follow-up requirements.